AR110165A1 - ANTI-MET ANTIBODIES, BIO-SPECIFIC MOLECULES OF ANTIGEN BINDING THAT BIND MET, AND METHODS OF USE - Google Patents
ANTI-MET ANTIBODIES, BIO-SPECIFIC MOLECULES OF ANTIGEN BINDING THAT BIND MET, AND METHODS OF USEInfo
- Publication number
- AR110165A1 AR110165A1 ARP170103179A ARP170103179A AR110165A1 AR 110165 A1 AR110165 A1 AR 110165A1 AR P170103179 A ARP170103179 A AR P170103179A AR P170103179 A ARP170103179 A AR P170103179A AR 110165 A1 AR110165 A1 AR 110165A1
- Authority
- AR
- Argentina
- Prior art keywords
- met
- binding
- antigen
- bispecific
- bispecific antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 10
- 102000036639 antigens Human genes 0.000 title abstract 10
- 108091007433 antigens Proteins 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 3
- 239000000611 antibody drug conjugate Substances 0.000 abstract 3
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000057421 human MET Human genes 0.000 abstract 2
- 108010066733 mRNA (guanine(N7))-methyltransferase Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
En la presente se proporcionan anticuerpos y moléculas biespecíficas de unión a antígeno que se unen a MET y sus métodos de uso. Las moléculas biespecíficas de unión a antígeno comprenden un primer y un segundo dominio de unión a antígeno, donde el primero y el segundo de los dominios se unen a dos epítopos diferentes (preferentemente sin superposición) del dominio extracelular de MET humano. Las moléculas biespecíficas de unión a antígeno son capaces de bloquear la interacción entre MET humano y su ligando HGF. Las moléculas biespecíficas de unión a antígeno pueden exhibir mínima o nula actividad agonista frente a MET, por ejemplo, en comparación con moléculas monovalentes de unión a antígeno que comprenden uno solo de los dominios de unión a antígeno de la molécula biespecífica, lo que tiende a ejercer una actividad agonista no deseada frente a MET. También se incluyen conjugados anticuerpo-fármaco (ADC) que comprenden los anticuerpos o las moléculas biespecíficas de unión a antígeno proporcionadas en la presente, conectadas con un agente citotóxico, un radionucleido, u otro resto, como así también métodos para tratar el cáncer en un sujeto mediante la administración al sujeto de una molécula biespecífica de unión a antígeno o un ADC de esta. Reivindicación 12: La molécula biespecífica de unión a antígeno de cualquiera de las reivindicaciones 1 a 11, donde D1 comprende tres regiones determinantes de complementariedad de cadena pesada (HCDR1, HCDR2 y HCDR3) dentro de una región variable de cadena pesada (HCVR) que comprende las secuencias de aminoácidos de SEQ ID Nº 58 y tres regiones determinantes de complementariedad de cadena ligera (LCDR1, LCDR2 y LCDR3) dentro de una región variable de cadena ligera (LCVR) que comprende la secuencia de aminoácidos de SEQ ID Nº 138.Antibody binding antibodies and bispecific molecules that bind to MET and their methods of use are provided herein. Bispecific antigen-binding molecules comprise a first and second antigen-binding domain, where the first and second of the domains bind to two different epitopes (preferably without overlapping) of the extracellular domain of human MET. Bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its HGF ligand. Bispecific antigen-binding molecules may exhibit minimal or no agonist activity against MET, for example, compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tends to exercise an unwanted agonist activity against MET. Also included are antibody-drug conjugates (ADC) comprising antibodies or bispecific antigen-binding molecules provided herein, connected with a cytotoxic agent, a radionuclide, or other moiety, as well as methods for treating cancer in a subject by administration to the subject of a bispecific antigen binding molecule or an ADC thereof. Claim 12: The bispecific antigen-binding molecule of any one of claims 1 to 11, wherein D1 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising The amino acid sequences of SEQ ID No. 58 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID No. 138.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423068P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110165A1 true AR110165A1 (en) | 2019-03-06 |
Family
ID=65895504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103179A AR110165A1 (en) | 2016-11-16 | 2017-11-15 | ANTI-MET ANTIBODIES, BIO-SPECIFIC MOLECULES OF ANTIGEN BINDING THAT BIND MET, AND METHODS OF USE |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR110165A1 (en) |
| MA (1) | MA45805B2 (en) |
-
2017
- 2017-11-15 MA MA45805A patent/MA45805B2/en unknown
- 2017-11-15 AR ARP170103179A patent/AR110165A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA45805B2 (en) | 2021-11-30 |
| MA45805A1 (en) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004955A2 (en) | Anti-met antibodies, bispecific antigen binding molecules that bind to met and methods of use thereof | |
| CR20180484A (en) | NEW B7-H3 UNON MOLECULES, ANTIBODY-DRUG CONJUGATES OF THE SAME AND METHODS OF USE OF THE SAME | |
| PE20181090A1 (en) | IMMUNE MODULATION AND TREATMENT OF SOLID TUMORS WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 | |
| AR126019A1 (en) | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES | |
| PE20210180A1 (en) | ANTI-CD33 ANTIBODIES, ANTI-CD33 / ANTI-CD3 BISPECIFIC ANTIBODIES AND USES OF THEM | |
| AR110017A1 (en) | PD-1 ANTIBODIES AND USES OF THESE | |
| AR110719A1 (en) | HUMAN ANTIBODIES TO HEMOLISINE TOXIN A DE S. AUREUS | |
| PE20200294A1 (en) | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE | |
| CY1121331T1 (en) | TREATMENT OF HEMATOLOGICAL MALIGRANTS WITH ANTI-CXCR4 | |
| AR110203A1 (en) | ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES | |
| PE20181326A1 (en) | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND ITS USES | |
| PE20181921A1 (en) | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS | |
| AR117911A2 (en) | ANTI-158P1D7 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION AND ITS USES | |
| MX2017005976A (en) | SPECIFIC UNION MOLECULES FOR DIFFERENTIATION GROUP 73 (CD73) AND USES OF THE SAME. | |
| AR102698A1 (en) | ANTIBODIES AGAINST CD73 AND ITS USES | |
| PE20171180A1 (en) | ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE | |
| PE20170903A1 (en) | DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES | |
| PE20181358A1 (en) | COMPOSITIONS OF ANTIBODY GRAFTED WITH CYTOKINE AND METHODS FOR ITS USE IN IMMUNOREGULATION | |
| AR098663A1 (en) | MULTIFUNCTIONAL ANTIBODIES THAT JOIN EGFR AND MET | |
| RU2017114968A (en) | BINDING MOLECULES, AND EXACTLY ANTIBODIES, ABLE TO CONTACT L1CAM (CD171) | |
| AR104906A1 (en) | ANTIBODIES DIRECTED TO THE BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS FROM THESE | |
| AR096601A1 (en) | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE | |
| HRP20161587T1 (en) | Bmp-6 antibodies | |
| PE20231080A1 (en) | ANTIBODIES THAT BIND CD3 AND CD19 | |
| BR112022009482A2 (en) | MONOCLONAL ANTI-B7-H3 ANTIBODY AND METHODS OF USE THEREOF |